Michael Rapp, 10% Owner at Zynerba Pharmaceuticals, Inc. (ZYNE), bought 15,000 shares at $12.99 ($195K) on 2018-01-02, disclosed to the SEC on 2018-01-03.
Open-market purchase of $195k ZYNE by 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| Filing → |
| IMNM | BUY | 2021-05-26 | $1.9M | — | Filing → |
| IMNM | BUY | 2020-10-08 | $1000K | — | Filing → |
| ZYNE | BUY | 2018-05-31 | $123K | — | Filing → |